CSTLHealthcare · Diagnostics & ResearchThe 9 Wall Street analysts covering Castle Biosciences, Inc. hold a median 12-month price target of $44 — +34.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Castle Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Growth (40): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CSTL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +34.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | BTIG | Maintains | Buy | $40 → $44 |
| 25 June 2026 | Roth Capital | Initiates | Buy | $40 |
| 25 June 2026 | Roth Capital | Initiates | Buy | — |
| 13 May 2026 | BTIG | Maintains | Buy | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Feb 2026 | Baird | Maintains | Outperform | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 12 Jan 2026 | Lake Street | Maintains | Buy | — |
| 5 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 12 Dec 2025 | BTIG | Maintains | Buy | — |
| 5 Nov 2025 | BTIG | Maintains | Buy | — |
| 4 Nov 2025 | Baird | Maintains | Outperform | — |
| 9 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 May 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 6 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 May 2025 | Lake Street | Maintains | Buy | — |
| 28 Feb 2025 | Baird | Maintains | Outperform | — |
| 2 Jan 2025 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CSTL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Castle Biosciences, Inc. returned +40.7% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 43% of US stocks
Cheaper than 43% of US stocks
Cheaper than 94% of US stocks
Higher than 70% of US stocks
Higher than 59% of US stocks
Higher than 89% of US stocks
Higher than 29% of US stocks
Higher than 23% of US stocks
Higher than 40% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Castle Biosciences, Inc. has a market value of $1.0B and an enterprise value of $791.4M.
Revenue in the twelve months to 30 June 2026: $357.3M. The latest quarter grew 20.1% year on year.
Net income over the same four quarters: −$19.4M, a −5.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.66.
Free cash flow in the twelve months to 30 June 2026: −$489K.
Trailing P/E: 30.5×; forward P/E: −33.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Castle Biosciences, Inc. employs 1,002 people — $357K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Castle Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article from Zacks Investment Research notes that Castle Biosciences, Inc. (CSTL) rose 15.46% over the past week. The piece examines whether the company could be a top pick for momentum investors.
Why it matters — For those tracking CSTL, the piece highlights a notable one-week price gain and evaluates the stock's potential appeal to momentum-focused investors.
Zacks Investment Research reports that the consensus price target for Castle Biosciences (CSTL) suggests roughly 31.5% upside potential. The article notes that while this metric is not highly effective on its own, an upward trend in earnings estimate revisions could indicate near-term upside for the stock.
Why it matters — CSTL watchers would care because the piece highlights the consensus price target and recent upward earnings estimate revisions, which could signal improving analyst sentiment around the company.
Castle Biosciences announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. The announcement was made by the company, which is listed on Nasdaq under the ticker CSTL.
Why it matters — Presenting at a major healthcare conference gives investors and analysts an opportunity to hear directly from Castle Biosciences' management about its business and strategy.
Castle Biosciences announced it has been approved for a dual listing of its common stock on Nasdaq Texas, a new exchange headquartered in Dallas. The company will retain its primary listing on The Nasdaq Global Market, with the stock expected to begin trading on Nasdaq Texas under the existing ticker "CSTL."
Why it matters — This expands Castle's trading venues and increases its visibility and accessibility to investors through the new Nasdaq Texas exchange.
Castle Biosciences reported continued momentum in its core diagnostic franchises during the second quarter. CFO Frank Stokes said the company raised its outlook by more than the amount of its reported beat.
Why it matters — A CSTL watcher would care because an outlook raise tied to core diagnostic momentum suggests strengthening performance in its key melanoma and tissue-based testing products.
The 9 Wall Street analysts covering Castle Biosciences, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Castle Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Castle Biosciences, Inc. 88 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Castle Biosciences, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +34.8% from the last close, and Ticker Nerd's factor model ranks Castle Biosciences, Inc. 88 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Castle Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $57 over the next 12 months.
Castle Biosciences, Inc. returned +40.7% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making.
The most recent item we track (Zacks Investment Research, 28 Aug 2026): "Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know". The article from Zacks Investment Research notes that Castle Biosciences, Inc. (CSTL) rose 15.46% over the past week. The piece examines whether the company could be a top pick for momentum investors.
Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making. The company focuses primarily on dermatologic cancers, including melanoma and cutaneous squamous cell carcinoma, while also serving gastroenterology, ophthalmology, and certain mental health applications. Its portfolio includes tests used to help assess risk, refine diagnosis, and guide treatment choices through clinically actionable genomic and molecular information. Castle Biosciences works with physicians, specialty clinics, hospitals, and health systems that rely on specialized testing to better manage complex diseases and personalize care. The company’s role in the market centers on translating laboratory science into practical tools that can improve how patients are evaluated and treated across several high-need medical areas.
CEO Mr. Derek J. Maetzold · 1,002 employees · United States · https://castlebiosciences.com
